A detailed history of Freestone Capital Holdings, LLC transactions in Abb Vie Inc. stock. As of the latest transaction made, Freestone Capital Holdings, LLC holds 64,112 shares of ABBV stock, worth $10.9 Million. This represents 0.44% of its overall portfolio holdings.

Number of Shares
64,112
Previous 66,272 3.26%
Holding current value
$10.9 Million
Previous $11.4 Million 11.38%
% of portfolio
0.44%
Previous 0.41%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$163.84 - $199.33 $353,894 - $430,552
-2,160 Reduced 3.26%
64,112 $12.7 Million
Q2 2024

Aug 13, 2024

SELL
$154.79 - $180.76 $197,976 - $231,192
-1,279 Reduced 1.89%
66,272 $11.4 Million
Q1 2024

May 14, 2024

BUY
$159.82 - $182.1 $648,709 - $739,143
4,059 Added 6.39%
67,551 $12.3 Million
Q4 2023

Feb 13, 2024

BUY
$137.6 - $154.97 $50,912 - $57,338
370 Added 0.59%
63,492 $9.84 Million
Q3 2023

Nov 14, 2023

BUY
$133.59 - $154.65 $346,398 - $401,007
2,593 Added 4.28%
63,122 $9.41 Million
Q2 2023

Aug 09, 2023

SELL
$132.51 - $164.9 $59,629 - $74,205
-450 Reduced 0.74%
60,529 $8.16 Million
Q1 2023

May 12, 2023

SELL
$144.61 - $166.54 $5,061 - $5,828
-35 Reduced 0.06%
60,979 $9.72 Million
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $1.35 Million - $1.62 Million
-9,745 Reduced 13.77%
61,014 $9.87 Million
Q3 2022

Nov 09, 2022

SELL
$134.21 - $153.93 $1.06 Million - $1.21 Million
-7,884 Reduced 10.03%
70,759 $9.5 Million
Q2 2022

Aug 09, 2022

SELL
$137.62 - $174.96 $1.73 Million - $2.2 Million
-12,571 Reduced 13.78%
78,643 $12 Million
Q1 2022

May 12, 2022

SELL
$131.98 - $163.75 $635,615 - $788,620
-4,816 Reduced 5.02%
91,214 $14.8 Million
Q4 2021

Feb 14, 2022

BUY
$107.43 - $135.93 $400,176 - $506,339
3,725 Added 4.04%
96,030 $13 Million
Q3 2021

Nov 15, 2021

BUY
$106.4 - $120.78 $1.08 Million - $1.23 Million
10,157 Added 12.36%
92,305 $9.96 Million
Q2 2021

Aug 16, 2021

BUY
$105.21 - $117.21 $109,523 - $122,015
1,041 Added 1.28%
82,148 $9.25 Million
Q1 2021

May 17, 2021

SELL
$102.3 - $112.62 $232,834 - $256,323
-2,276 Reduced 2.73%
81,107 $8.78 Million
Q4 2020

Feb 16, 2021

BUY
$80.49 - $108.67 $872,189 - $1.18 Million
10,836 Added 14.94%
83,383 $8.93 Billion
Q3 2020

Nov 06, 2020

BUY
$85.91 - $100.83 $79,810 - $93,671
929 Added 1.3%
72,547 $6.35 Million
Q2 2020

Aug 04, 2020

BUY
$73.37 - $98.18 $1.26 Million - $1.69 Million
17,179 Added 31.56%
71,618 $7.03 Million
Q1 2020

May 12, 2020

BUY
$64.5 - $97.79 $486,459 - $737,532
7,542 Added 16.08%
54,439 $4.15 Million
Q4 2019

Feb 04, 2020

SELL
$72.13 - $90.25 $555,256 - $694,744
-7,698 Reduced 14.1%
46,897 $4.15 Million
Q3 2019

Nov 07, 2019

SELL
$62.98 - $75.72 $376,746 - $452,957
-5,982 Reduced 9.88%
54,595 $4.13 Million
Q2 2019

Aug 05, 2019

SELL
$65.7 - $83.98 $216,021 - $276,126
-3,288 Reduced 5.15%
60,577 $4.41 Million
Q1 2019

May 08, 2019

SELL
$77.14 - $90.79 $2.61 Million - $3.07 Million
-33,865 Reduced 34.65%
63,865 $5.15 Million
Q4 2018

Feb 12, 2019

SELL
$77.85 - $96.01 $884,843 - $1.09 Million
-11,366 Reduced 10.42%
97,730 $9.01 Million
Q3 2018

Nov 13, 2018

BUY
$88.91 - $98.84 $666,647 - $741,102
7,498 Added 7.38%
109,096 $10.3 Million
Q2 2018

Aug 14, 2018

BUY
$89.78 - $106.23 $2.28 Million - $2.7 Million
25,374 Added 33.29%
101,598 $9.41 Million
Q1 2018

May 15, 2018

BUY
$92.01 - $123.21 $27,418 - $36,716
298 Added 0.39%
76,224 $7.22 Million
Q4 2017

Feb 13, 2018

BUY
$89.56 - $98.21 $30,450 - $33,391
340 Added 0.45%
75,926 $7.34 Million
Q3 2017

Nov 14, 2017

BUY
$69.85 - $89.22 $273,113 - $348,850
3,910 Added 5.46%
75,586 $6.72 Million
Q2 2017

Aug 15, 2017

BUY
N/A
71,676
71,676 $5.2 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $300B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Freestone Capital Holdings, LLC Portfolio

Follow Freestone Capital Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Freestone Capital Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Freestone Capital Holdings, LLC with notifications on news.